McKesson (NYSE:MCK) Stock Gets Price Target Bump from Royal Bank Of Canada

McKesson (NYSE:MCK) had its price target raised by Royal Bank Of Canada from $845.00 to $965.00 in a report released on Thursday, Benzinga reports. The firm currently has a “sector perform” rating on the stock. Royal Bank Of Canada‘s price objective points to a potential downside of 9.03% from the company’s current price.

Several other research firms also recently commented on MCK. Citigroup increased their price objective on McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, July 24th. Bank of America boosted their target price on shares of McKesson from $950.00 to $1,050.00 in a report on Thursday, August 6th. Barclays upped their price target on shares of McKesson from $925.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 19th. Mizuho increased their price target on shares of McKesson from $905.00 to $1,020.00 and gave the company a “neutral” rating in a research note on Tuesday, October 20th. Finally, Evercore reissued an “outperform” rating and issued a $950.00 price objective (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. Fifteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1,026.18.

McKesson Stock Performance

MCK traded down $11.21 on Thursday, hitting $1,060.79. 812,129 shares of the company were exchanged, compared to its average volume of 691,239. McKesson has a 12 month low of $723.68 and a 12 month high of $1,121.50. The company has a market cap of $123.68 billion, a PE ratio of 27.28, a PEG ratio of 1.99 and a beta of 0.27. The stock’s fifty day moving average is $938.13 and its 200-day moving average is $868.12.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, beating the consensus estimate of $10.72 by $0.96. The firm had revenue of $110.96 billion during the quarter, compared to analysts’ expectations of $109.90 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $9.86 earnings per share. As a group, equities research analysts expect that McKesson will post 45.26 EPS for the current fiscal year.

Insider Transactions at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total value of $98,950.95. Following the transaction, the chief accounting officer directly owned 521 shares of the company’s stock, valued at $464,445.45. This represents a 17.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley E. Lerman sold 301 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $892.33, for a total transaction of $268,591.33. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 2,462 shares of company stock worth $2,511,106. 0.06% of the stock is owned by insiders.

Hedge Funds Weigh In On McKesson

Institutional investors and hedge funds have recently made changes to their positions in the company. Nvwm LLC increased its stake in shares of McKesson by 933.3% during the third quarter. Nvwm LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 28 shares during the period. Delos Wealth Advisors LLC bought a new stake in McKesson in the 2nd quarter valued at $27,000. Trellis Wealth Advisors LLC bought a new stake in McKesson in the 3rd quarter valued at $32,000. GK Wealth Management LLC bought a new stake in McKesson in the 3rd quarter valued at $38,000. Finally, Curry Webb Wealth Management LLC acquired a new position in McKesson in the 3rd quarter valued at $38,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.